Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. USO
6. AMD
7. TSLA
8. COHR
9. META
10. ACN

Go back to Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
(NASDAQ: ROIV) Delayed: 38.99 --0 (-0%)
Previous Close $38.99    52 Week High $ 
Open $38.99    52 Week Low $ 
Day High $38.99    P/E N/A 
Day Low $38.99    EPS $ 
Volume 2,517       

(NASDAQ: ROIVW) Delayed: 2.75 --0 (-0%)
Previous Close $2.75    52 Week High $ 
Open $25.55    52 Week Low $ 
Day High $2.75    P/E N/A 
Day Low $2.75    EPS $ 
Volume 555